HomeCompareCRPOF vs EPRT

CRPOF vs EPRT: Dividend Comparison 2026

CRPOF yields 1176.47% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRPOF wins by $78814195.14M in total portfolio value
10 years
CRPOF
CRPOF
● Live price
1176.47%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78814195.20M
Annual income
$67,523,701,253,088.38
Full CRPOF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — CRPOF vs EPRT

📍 CRPOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRPOFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRPOF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRPOF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRPOF
Annual income on $10K today (after 15% tax)
$100,000.00/yr
After 10yr DRIP, annual income (after tax)
$57,395,146,065,125.13/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, CRPOF beats the other by $57,395,146,053,929.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRPOF + EPRT for your $10,000?

CRPOF: 50%EPRT: 50%
100% EPRT50/50100% CRPOF
Portfolio after 10yr
$39407097.63M
Annual income
$33,761,850,633,129.62/yr
Blended yield
85.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CRPOF
No analyst data
Altman Z
3.3
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRPOF buys
0
EPRT buys
0
No recent congressional trades found for CRPOF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRPOFEPRT
Forward yield1176.47%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$78814195.20M$64.3K
Annual income after 10y$67,523,701,253,088.38$13,170.85
Total dividends collected$77969765.27M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CRPOF vs EPRT ($10,000, DRIP)

YearCRPOF PortfolioCRPOF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$128,347$117,647.06$11,212$512.01+$117.1KCRPOF
2$1,548,514$1,411,182.61$12,689$692.09+$1.54MCRPOF
3$17,569,052$15,912,142.01$14,521$944.30+$17.55MCRPOF
4$187,523,354$168,724,468.35$16,841$1,302.88+$187.51MCRPOF
5$1,883,716,681$1,683,066,692.55$19,841$1,821.64+$1883.70MCRPOF
6$17,816,329,317$15,800,752,468.33$23,818$2,587.47+$17816.31MCRPOF
7$158,731,384,105$139,667,911,735.60$29,230$3,744.65+$158731.35MCRPOF
8$1,332,782,916,056$1,162,940,335,063.89$36,816$5,540.38+$1332782.88MCRPOF
9$10,551,863,503,163$9,125,785,782,982.70$47,806$8,413.17+$10551863.46MCRPOF
10$78,814,195,201,473$67,523,701,253,088.38$64,324$13,170.85+$78814195.14MCRPOF

CRPOF vs EPRT: Complete Analysis 2026

CRPOFStock

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. It operates in two segments, Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment develops proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients sold directly to the end-user primarily through online website sales and through select natural products stores. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Full CRPOF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CRPOF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRPOF vs SCHDCRPOF vs JEPICRPOF vs OCRPOF vs KOCRPOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.